Erasca Inc.shares plunged as much as 55% Tuesday after the cancer-drug developer said one patient withdrew from its clinical trial and later died after suffering severe side effects related to the treatment.
The patient, a 66-year-old man, went to the emergency room with severe lung inflammation about a month after starting the company’s therapy. He subsequently died after discontinuing the treatment.
With Pam Bondi out (related?), the U.S. Department of Justiceannounced todaythat it has indicted Dr. David M. Morens,a longtime senior advisor to former National Institute of Allergy and Infectious Diseases DirectorDr. Anthony Fauci.The 78-year-old Morens faces charges includingconspiracy against the United States, destruction, alteration, or falsification of records in federal investigations, concealment, removal, or mutilation of records, and aiding and abetting.
According to the indictment, Morens allegedly used his personal Gmail account to evade Freedom of Information Act requests and worked with others to conceal communications related to COVID-19 research grants during the pandemic.
Fauci advisor David Morens admits in an email that he "learned from our foia lady here how to make emails disappear after i am foia'd but before the search starts" https://t.co/sn6hvwDF7Rpic.twitter.com/1MroXRWNQO
Morens served as Senior Scientific Advisor in NIAID’s Office of the Director from 2006 through 2022 - advising senior leadership, including Fauci, on policy matters, infectious disease issues, and aspects of COVID-19 origins research. He also gathered information from grantees and the scientific community and helped prepare briefings for Fauci to use with the White House, Congress, and the public.
The Congressional Investigation
The indictment follows years of scrutiny by Congress. In June 2023, the House Select Subcommittee on the Coronavirus Pandemic began obtaining emails showing that Morens had been using his personal Gmail account for official government business specifically to avoid FOIA disclosures. Over the following months the subcommittee issued document requests and subpoenas, conducted transcribed interviews with Morens in December 2023 and January 2024, and ultimately obtained tens of thousands of additional pages from his personal email account in late April 2024.
As Paul Thacker of the DisInformation Chroniclenoted in 2024, the subcommittee released a detailed staff memo and more than 150 pages of emails on May 22, 2024, documenting what it described as serious questions about potential wrongdoing and illegal activity by Morens. The emails included discussions of deleting records and routing sensitive communications through personal accounts.
Sen. Ron Johnson had raised similar concerns even earlier. In November 2023 he wrote to HHS Secretary Xavier Becerra and Inspector General Christi Grimm, stating that Morens’ actions may have directly obstructed congressional oversight efforts related to NIAID activities during the pandemic.
More than two years ago, my PSI staff discovered and made public emails in which Dr. David Morens bragged to colleagues about his efforts to avoid transparency by destroying federal records and using his personal email to communicate on “sensitive issues.”
Two emails in particular have drawn significant attention. In a February 24, 2021 message to Peter Daszak of EcoHealth Alliance and Gerald Keusch, Morens wrote that he had learned from an NIH FOIA official “how to make emails disappear after I am FOIA’d but before the search starts, so I think we are all safe. Plus, I deleted most of those earlier emails after sending them to Gmail."
In an April 21, 2021 email to Daszak, Morens added: “PS, I forgot to say there is no worry about FOIAs. I can either send stuff to Tony on his private gmail, or hand it to him at work or at his house. He is too smart to let colleagues send him stuff that could cause trouble." (“Tony" refers to Anthony Fauci.)
These messages, along with others detailing coordination with EcoHealth Alliance after its NIH grant was terminated, formed a central part of the congressional record.
'Tie Your Shoe'
On May 22, 2024, Morens appeared for a public hearing before the Select Subcommittee on the Coronavirus Pandemic. He faced questions from both Republican and Democratic members about the emails, his relationship with Daszak, and his role in efforts to restore EcoHealth’s terminated grant and shape public messaging around COVID-19 origins.
During the hearing, Morens was confronted with evidence that he:
Edited compliance letters and press releases for EcoHealth Alliance
Wrote to the EcoHealth board on Daszak’s behalf when the latter feared being fired
Used personal email to route information to Fauci while attempting to avoid FOIA
Discussed methods for deleting or hiding emails after FOIA requests had been filed
As Paul Thacker writes:
Reading back to Morens passages from his own emails and prior congressional testimony, Chairman Brad Wenstrup forced Morens to confirm that he had conspired with EcoHealth Alliance’s Peter Daszak to restore Daszak’s NIH grant. Morens admitted that he edited a compliance letter Daszak sent to the NIH, edited an EcoHealth Alliance press release after NIH terminated Daszak’s grant, and “put in a word” to the EcoHealth Alliance board when Daszak was worried about being fired.
Ranking Member Raul Ruiz berated Morens at several points, saying his actions were a “stain on the legacy” of the NIH and his colleagues. After Wenstrup banged down his gavel to end the hearing, Morens remained seated and was approached by his lawyer, white collar crime attorney Timothy Belevetz.
The indictment alleges that after NIH terminated EcoHealth Alliance’s grant Understanding the Risk of Bat Coronavirus Emergence — which included a subaward to the Wuhan Institute of Virology — Morens and unnamed co-conspirators conspired to help restore the grant and counter the lab-leak narrative. The charges further claim that Morens used his personal Gmail account to hide these communications from public view and that he received illegal gratuities, including wine delivered to his home, in connection with official acts favorable to EcoHealth.
Maximum penalties if convicted:
Conspiracy against the United States: up to 5 years in prison
Destruction, alteration, or falsification of records in federal investigations: up to 20 years per count
Concealment, removal, or mutilation of records: up to 3 years per count
An indictment is not a finding of guilt. All defendants are presumed innocent until proven guilty in a court of law.
Timeline of Key Events
2020–2021: Key emails written regarding FOIA avoidance, back-channel communications, and coordination with EcoHealth Alliance
June 2023: House Select Subcommittee begins obtaining Morens’ personal emails
October 2023: Morens subpoenaed for documents
November 2023: Sen. Ron Johnson raises concerns with HHS leadership about potential obstruction of oversight
December 2023 and January 2024: Morens gives transcribed interviews to the subcommittee
April 2024: Additional subpoena issued; Morens produces roughly 30,000 pages of emails
May 22, 2024: Public hearing held and staff memo plus 155 pages of emails released
June 3, 2024: Dr. Anthony Fauci testifies before the subcommittee
April 28, 2026: Department of Justice indicts David Morens
Broader Context: The Offshoring of Risky U.S. Research
In 2014, the Obama administration imposed a pause on federal funding for certain gain-of-function research on pathogens such as influenza, SARS, and MERS viruses, citing serious biosafety concerns following several laboratory incidents. The moratorium was lifted in 2017, but by then much of the work had effectively moved overseas. EcoHealth Alliance, led by Peter Daszak, continued receiving millions in NIH grants for bat coronavirus research - with a significant portion funneled through subawards to the Wuhan Institute of Virology (WIV) in Wuhan, China.
At the same time, University of North Carolina virologist Ralph Baric - one of the world’s leading experts on coronaviruses - had been collaborating closely with WIV scientists, including Shi Zhengli, in work described in a 2018 DEFUSE funding proposal (that was rejected by DARPA) to create an aerosolized bat covid that could infect humans. Baric’s lab created “humanized mice” expressing the human ACE2 receptor and engineered chimeric viruses to study how bat coronaviruses could jump to humans. Much of this high-risk work, which had previously been conducted on U.S. soil, was effectively transferred to the WIV - located in the very city where COVID-19 first emerged.
Details of the DEFUSE project were first leaked by Major Joseph Murphy, an employee of US military research agency DARPA, in the summer of 2021 and further details of earlier drafts have come to light this month thanks to public record requests from U.S. Right to Know (USRTK).
In DEFUSE, Baric proposed to create a virus that was, to most intents and purposes, SARS-CoV-2. The proposal included inserting a furin cleavage site into a coronavirus spike protein, an order for the restrictive enzyme BsmBI, the search for a binding domain that would infect ACE2 human receptors and a requirement for a viral genome around 25% different to SARS.
One down (until Boasberg knights him), many to go.
Loaded Idemitsu Maru crude supertanker exited Hormuz this afternoon, marking the first such crude transit since the conflict began.
Loaded Mubaraz LNG tanker exited Hormuz earlier this month, also marking the first such LNG transit since the conflict began.
Polymarket
First Crude Supertanker Exits Hormuz
Following the Mubaraz LNG tanker's exit from the Hormuz chokepoint in recent weeks, the first such transit since the conflict began, new ship-tracking data from Bloomberg late Tuesday afternoon show that the first crude supertanker, Idemitsu Maru, is also exiting the critical waterway.
Idemitsu Maru, operated by the tanker unit of Japan's Idemitsu Kosan, marks yet another positive signal for Gulf energy flows, but activity in the waterway remains deeply depressed.
Two key things we must point out: first, the tanker is through; second, the tanker did not transit the Larak Channel, the northern passage through the critical waterway near Iran's Larak Island, close to Qeshm Island.
First Loaded LNG Tanker Clears Hormuz; First Crude Supertanker Attempts Exit
While all the attention has been focused on President Trump's national security team reviewing an Iranian peace deal that would end the two-month war and reopen the Hormuz chokepoint, while deferring nuclear negotiations to a later date, new vessel-tracking data show that the first loaded LNG tanker has exited the critical waterway since the conflict began, while the first loaded crude supertanker is also attempting to exit.
"The first LNG shipment since the war in Iran began two months ago appears to have slipped through Hormuz," Bloomberg's Stephen Stapczynski wrote in an overnight post on X.
Stapczynski also noted that the Mubaraz LNG tanker was loaded at ADNOC's Das Island facility in Abu Dhabi in early March and turned off its transponder around March 31, only reappearing west of India on Monday.
The latest ship-tracking data from Bloomberg shows that Mubaraz is approaching the southern tip of Sri Lanka, with the vessel signaling China as its port of call.
A separate report from Bloomberg's Weilun Soon identified yet another tanker, this time a Japan-linked supertanker loaded with crude, attempting to become the first crude-laden vessel to exit Hormuz since the war began.
The Idemitsu Maru, operated by the tanker unit of Japan's Idemitsu Kosan, left its holding position near Abu Dhabi late Monday and appears to be exiting the Hormuz chokepoint early Tuesday, according to Bloomberg ship-tracking data.
Both transits are significant. Taken together, they may indicate that a U.S.-Iran framework to end the war and reopen the critical waterway is nearing execution, or that countries such as China and Japan are beginning to see a pathway toward de-escalation.
The latest Polymarket odds of Hormuz traffic returning to normal by May 15 stand at around 15%.
Anticipation of CEO's oral showcase of positive Phase 3 ARDS data at ATS Summit drives EDSA surge.
Edesa Biotech’s shares jumped on extremely elevated volume (over 9 million shares on April 27 versus typical daily volume under 400,000) after trading in the $6–7 range in prior sessions. The move reflects building momentum ahead of CEO Dr. Par Nijhawan’s selection to deliver the inaugural presentation at the ATS 2026 Respiratory Innovation Summit Oral Showcase on May 15. There, he is scheduled to present findings from the company’s Phase 3 trial of paridiprubart (EB05), an anti-TLR4 antibody for Acute Respiratory Distress Syndrome, which previously demonstrated statistically significant mortality reductions (including a 27% relative risk reduction in broader populations per February 2026 updates). This extends interest from the March 31 announcement of the invitation, recent vitiligo program progress toward mid-2026 enrollment, a modest Q1 earnings beat, analyst Buy ratings, and characteristics of a low-float microcap biotech (roughly 9 million shares outstanding) prone to rapid retail-driven moves. No new press release appeared on April 27–28, but the conference catalyst and prior positive data provided clear fuel.